Results 11 to 20 of about 73,193 (159)
Haematologica, 2017 In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski +10 more
doaj +1 more source
Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Prague Medical Report, 2023 Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities
Athanasios J. Stefanis
doaj +1 more source
The use of Tofacitinib in the treatment of inflammatory bowel disease [PDF]
Терапевтический архив, 2019 Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus ...
E L Nasonov +2 more
doaj +1 more source
Therapeutic targeting of Janus kinases [PDF]
Immunological Reviews, 2008 SummaryCytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders. Type I and II cytokine receptors associate with Janus family kinases (JAKs) to effect intracellular signaling.
Marko, Pesu +5 more
openaire +2 more sources
The Emerging World of JAK Inhibitors
Nepal Journal of Dermatology, Venereology & LeprologyThe Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several ...
Shraddha Uprety
doaj +3 more sources
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
Haematologica, 2014 Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics +13 more
doaj +1 more source
Acta Dermato-Venereologica, 2022 The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and
Farnam B. Sedeh +3 more
doaj +1 more source
Janus kinase inhibitors: between prescription authorization and reimbursability
Reumatismo, 2023 Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria ...
F.R. Spinelli +5 more
doaj +1 more source
Janus kinase inhibitors: jackpot or potluck?
Oncology Reviews, 2012 The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +1 more source
BMC Infectious Diseases, 2021 Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz +6 more
doaj +1 more source